
Eupraxia Pharmaceuticals Inc. (EPRX) Stock Ticker
EPRX right now
Market factors today
Unlock the full EPRX picture
About Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
EPRX stock facts
| Ticker symbol | EPRX |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $268.2M |
| CEO | James A. Helliwell |
| Employees | 49 |
| Headquarters | Victoria, BC, CA |
| IPO date | 2024-04-05 |
| Website | www.eupraxiapharma.com |
What you can see for EPRX on Tickr
Live EPRX price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the EPRX report.
Rankings
FAQ
What is the ticker symbol for Eupraxia Pharmaceuticals Inc.?
The ticker symbol for Eupraxia Pharmaceuticals Inc. is EPRX, listed on the NASDAQ.
What is EPRX?
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee…